The development of specific therapeutics against essential cytokines in the IL-23/IL-17 axis is a good illustration of how basic and translational immunological research has led to the development of highly potent drugs that can effectively and safely treat most patients with at least moderate psoriasis. This evidence concerns the gene IL17A and psoriasis.